Summary
Corteva, Inc. reported net sales of $6.045 billion for the second quarter of 2023, a 3% decrease compared to the prior year, primarily driven by a 13% volume decline, partially offset by a 9% increase in price. The six-month period showed a 1% increase in net sales to $10.929 billion, with an 11% price increase offsetting a 9% volume decline. Net income for the quarter was $714 million ($1.00 per diluted share), down from $969 million ($1.33 per diluted share) in the same period last year. The company completed significant acquisitions of Stoller and Symborg in March 2023, integrating biological and microbiological technologies into its crop protection portfolio. Despite overall sales challenges, the company highlighted strong price execution and ongoing cost and productivity initiatives, while also managing increased interest expenses and investing in R&D.
Financial Highlights
53 data pointsBeta
Financial Statements
Beta
| Revenue | $6.04B |
| Cost of Revenue | $3.14B |
| Gross Profit | $2.91B |
| R&D Expenses | $329.00M |
| SG&A Expenses | $1.04B |
| Net Income | $714.00M |
| EPS (Basic) | $1.00 |
| EPS (Diluted) | $1.00 |
| Shares Outstanding (Basic) | 710.80M |
| Shares Outstanding (Diluted) | 713.70M |
Key Highlights
- 1Net sales for Q2 2023 decreased by 3% to $6.045 billion, impacted by lower volumes (-13%) but supported by price increases (+9%).
- 2For the first six months of 2023, net sales increased by 1% to $10.929 billion, driven by an 11% price increase which more than offset a 9% volume decrease.
- 3Net income for Q2 2023 was $714 million ($1.00 per diluted share), a decrease from $969 million ($1.33 per diluted share) in Q2 2022.
- 4The company completed the acquisitions of Stoller and Symborg for approximately $1.6 billion in March 2023, bolstering its biologicals and microbiological technologies offerings within the Crop Protection segment.
- 5Restructuring and asset-related charges decreased significantly to $60 million in Q2 2023 from $143 million in Q2 2022.
- 6Interest expense more than quadrupled to $82 million in Q2 2023 from $16 million in Q2 2022, largely due to higher interest rates and recent debt issuances.
- 7The company updated its full-year 2023 outlook, now expecting net sales between $17.9 billion and $18.2 billion and Operating EBITDA between $3.50 billion and $3.65 billion.
Frequently Asked Questions
Net sales in Q2 2023 decreased by 3% to $6.045 billion. This was primarily due to a 13% decrease in volume, influenced by factors such as lower corn planted area in EMEA, reduced soybean acres in North America, crop protection inventory destocking, weather-related demand timing, strategic product exits, and the Russia exit. These decreases were partially offset by a 9% increase in price, driven by Corteva's 'price for value' strategy, and a 2% favorable impact from portfolio changes, notably the biologicals acquisitions.
Corteva acquired Stoller and Symborg for approximately $1.6 billion in March 2023. While the combined operating results did not have a material impact on the interim financial statements, these acquisitions significantly supplement the crop protection business with biological and microbiological technologies. They contributed to a favorable portfolio impact on net sales and are expected to enhance the company's offerings in evolving farming practices. The acquisitions also contributed to increased Selling, General & Administrative (SG&A) expenses and intangible asset amortization.
Corteva updated its full-year 2023 guidance, now expecting net sales in the range of $17.9 billion to $18.2 billion and Operating EBITDA between $3.50 billion and $3.65 billion. This outlook reflects the agricultural sector's positive fundamentals, including strong demand for grains and oilseeds and healthy farm balance sheets. However, the guidance was lowered due to factors like crop protection inventory destocking, timing of seasonal demand, and currency impacts. The outlook does not account for extreme weather events or significant shifts in global economic conditions.
Interest expense significantly increased to $82 million in Q2 2023 from $16 million in Q2 2022. This rise is primarily attributed to higher interest rates on existing and new debt, along with the issuance of $1.2 billion in Senior Notes in May 2023 (maturing in 2026 and 2033). The company also utilized more short-term borrowings. This increase impacts profitability and is a key consideration for financial leverage.